A triple-agonist (GLP-1/GIP/glucagon) studied for the strongest weight-loss results in its class.
In the literature, Retatrutide appears most often in work focused on weight loss, appetite control and metabolism. Studies in this area tend to look at mechanisms and observed effects in laboratory and preclinical settings rather than outcomes in people, so the picture is best read as a map of where researchers have been curious — not as evidence of any benefit.
Retatrutide is catalogued here under powder peptides. Coverage of this compound varies in quality and depth, and much of it remains early-stage. Reading the underlying research directly is the only way to judge how strong any particular finding is.
Tap a topic to see which peptides are most studied for it.
AOD-9604 is a synthetic peptide fragment of human growth hormone, engineered to retain fat-burning properties without promoting tissue growth or elevated blood sugar. It is studied for its potential role in weight loss and metabolism regulation.
An amylin analog studied for appetite regulation and weight loss, often researched alongside GLP-1 compounds.
A GLP-1 receptor agonist extensively studied for appetite suppression, weight loss, and glucose control.
Research use only. This page summarizes areas of published study and is not medical advice. No dosing, protocol, or usage guidance is provided.